- Home
- ANIX vs ALEC Comparison
ANIX vs ALEC Comparison
Compare ANIX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ALEC
- Stock Information
- Founded
- ANIX 1982
- ALEC 2013
- Country
- ANIX United States
- ALEC United States
- Employees
- ANIX N/A
- ALEC N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- ALEC Health Care
- Exchange
- ANIX Nasdaq
- ALEC Nasdaq
- Market Cap
- ANIX 108.9M
- ALEC 124.0M
- IPO Year
- ANIX 1987
- ALEC 2019
- Fundamental
- Price
- ANIX $3.15
- ALEC $1.67
- Analyst Decision
- ANIX Strong Buy
- ALEC Buy
- Analyst Count
- ANIX 3
- ALEC 7
- Target Price
- ANIX $9.00
- ALEC $4.70
- AVG Volume (30 Days)
- ANIX 245.2K
- ALEC 558.7K
- Earning Date
- ANIX 09-05-2025
- ALEC 08-06-2025
- Dividend Yield
- ANIX N/A
- ALEC N/A
- EPS Growth
- ANIX N/A
- ALEC N/A
- EPS
- ANIX N/A
- ALEC N/A
- Revenue
- ANIX N/A
- ALEC $88,339,000.00
- Revenue This Year
- ANIX N/A
- ALEC N/A
- Revenue Next Year
- ANIX N/A
- ALEC $319.82
- P/E Ratio
- ANIX N/A
- ALEC N/A
- Revenue Growth
- ANIX N/A
- ALEC N/A
- 52 Week Low
- ANIX $2.07
- ALEC $0.87
- 52 Week High
- ANIX $4.20
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- ANIX 49.47
- ALEC 58.62
- Support Level
- ANIX $3.18
- ALEC $1.41
- Resistance Level
- ANIX $3.39
- ALEC $1.56
- Average True Range (ATR)
- ANIX 0.18
- ALEC 0.11
- MACD
- ANIX -0.05
- ALEC -0.00
- Stochastic Oscillator
- ANIX 4.55
- ALEC 95.96
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.